Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials
- PMID: 22638907
- DOI: 10.1007/s11886-012-0274-x
Revascularization for left main and multivessel coronary artery disease in the drug-eluting stent era: integration of recent drug-eluting stent trials
Abstract
As older patients comprise a greater proportion of the population, the incidence of multivessel and left main coronary artery disease is increasing. Given the improvements in percutaneous coronary intervention, more patients are suitable for this revascularization strategy. However, the optimal revascularization strategy remains a moving target. Numerous trials, extending from the bypass surgery versus medical therapy era to the most current drug-eluting stent versus bypass surgery era, provide information to select the most appropriate revascularization strategy. The objective of this review is to summarize these data.
Similar articles
-
Percutaneous Coronary Intervention of Left Main Disease: Pre- and Post-EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization Study) Era.Circ Cardiovasc Interv. 2017 Jun;10(6):e004792. doi: 10.1161/CIRCINTERVENTIONS.117.004792. Circ Cardiovasc Interv. 2017. PMID: 28607000 Review.
-
Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008. JACC Cardiovasc Interv. 2016. PMID: 28007199
-
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.JACC Cardiovasc Interv. 2010 Dec;3(12):1229-39. doi: 10.1016/j.jcin.2010.09.014. JACC Cardiovasc Interv. 2010. PMID: 21232716
-
Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the Asan Medical Center-Multivessel Revascularization Registry.J Am Coll Cardiol. 2011 Jan 11;57(2):128-37. doi: 10.1016/j.jacc.2010.09.022. J Am Coll Cardiol. 2011. PMID: 21211683
-
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071. J Am Coll Cardiol. 2018. PMID: 30025574
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials